Theralase Technologies (Theralase Technologies) 6-1 Month Momentum % : -0.56% (As of May. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-26), Theralase Technologies's 6-1 Month Momentum % is -0.56%.

The industry rank for Theralase Technologies's 6-1 Month Momentum % or its related term are showing as below:

TLTFF's 6-1 Month Momentum % is ranked better than
54.09% of 869 companies
in the Medical Devices & Instruments industry
Industry Median: -8.36 vs TLTFF: -0.56

Competitive Comparison of Theralase Technologies's 6-1 Month Momentum %

For the Medical Devices subindustry, Theralase Technologies's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's 6-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's 6-1 Month Momentum % falls into.

Theralase Technologies (OTCPK:TLTFF) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies (OTCPK:TLTFF) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Theralase Technologies 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (Theralase Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.